TriVascular Technologies Inc

TriVascular Technologies — Merger or Acquisition (November 2015)

105 slides from TriVascular Technologies's merger presentation, Nov 20, 2015

  1. Slide 1: Investor Meeting, VEITH Symposium

    Filed by Endologix, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of Subject Company: TriVascular Technologies, Inc. Commission File No.: 001-36419 Investor Meeting VEITH Symposium NOVEMBER 19, 2015 CONFIDENTIAL Fil

  2. Slide 2: Safe Harbor

    Safe Harbor Endologix and TriVascular will remain separate operational entities until the closing of the proposed merger transaction. Until closing, Endologix will not offer TriVascular products and TriVascular will not offer Endologix products. Forward-Looking Statements This presentation includes

  3. Slide 3: Agenda

    Agenda ? Market & Business Update J. McDermott ? Financials & Forecasts V. Mahboob ? EVAS Global Registry A. Holden, M.D. ? Treatment of Complex AAA M. Thompson, M.D. ? TriVascular Ovation D. Minion, M.D. ? Summary J. McDermott ? Q&A

  4. Slide 4: Endologix Vision

    Endologix Vision To provide confidence to patients and physicians as the leading global innovator of aortic therapies

  5. Slide 5: \ Ss A ae. ;

    |: y Bs I, ¥ \ 4 Ss A ae. ; bah 9 J : Eas bi Pkt ‘

  6. Slide 6: $3.3B AAA Market Opportunity

    $3.3B AAA Market Opportunity $3.3B $2.7B $1.0 $0.9 $0.5 Complex AAA $0.3 $0.3 Opportunity Billions Treated – 28% $ $0.3 Traditional AAA $1.5 Opportunity $1.2 Treated – 78% 2015 2020

  7. Slide 7: Only Company with Both EVAR and EVAS Solutions

    Only Company with Both EVAR and EVAS Solutions (post merger) Combined portfolio enables physicians to treat the most patients within IFU EVAR EVAS TriVascular Ovation Endologix AFX Endologix Nellix ? Proximal fixation ? Anatomical Fixation ? AAA fixation ? Ultra-low profile ? Preserve bifurcation ?

  8. Slide 8: Optimal Treatment Options for Each AAA Patient

    Optimal Treatment Options for Each AAA Patient AAA Anatomy and Prevalence Nellix AFX Ovation STANDARD ANATOMY 40%??? CHALLENGING NECKS Short Necks 36%? Reverse Taper Necks 33%??? Necks w/Thrombus 14%?? Angled Necks (>60°) 9% CHALLENGING ACCESS Ectatic Iliacs 36%? Narrow Distal Aorta 28%?? (<16mm) Sm

  9. Slide 9: Most Comprehensive AAA Product Line

    Most Comprehensive AAA Product Line (post merger)

  10. Slide 10: Significant Clinical Evidence To Drive Adoption

    Significant Clinical Evidence To Drive Adoption (post merger) 1,699 1,699 1,296 1,296 1,350 1,200 1,041 1,049 4,300+ 579 Patients TriVascular Endologix Endologix Enrolled by OVATION AFX NELLIX 2017 2015 2016 2017 2015 2016 2017 2015 2016 2017 ? IDE/CAP/PAS ? IDEs ? Global Registry ? Global Registry

  11. Slide 11: Expanded Global Sales Force

    Expanded Global Sales Force (post merger) ? World-class team of trained sales representatives and clinical specialists? ~200 sales reps, clinical specialists and agents worldwide – 30% increase? Customers in 44 countries across five continents

  12. Slide 12: Key Milestones to Nellix US Approval

    Key Milestones to Nellix US Approval* 2016 2017 Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Submit M3 PMA Approval* Submit M2 Presentation of 1 year IDE clinical data Submit M4 *Based upon current timelines and assumptions

  13. Slide 13: Nellix U.S. Physician Training Program

    Nellix U.S. Physician Training Program Following PMA approval, plan to train ~50 physicians/month Q1 Q2 Q3 Q4 Q5 Physician Trainee Demographics 50% Loyal ELGX Users 50% New Users

  14. Slide 14: Complex AAA Represents $1.5B Market Opportunity

    Complex AAA Represents $1.5B Market Opportunity Ovation Nellix Alto ChEVAS Ability to treat necks <10mm Ability to extend seal zone above renals 1/3 of Complex Patients 2/3 of Complex Patients *Market Size and Penetration Based on Company Estimates

  15. Slide 15: New Product Pipeline Provides Significant Growth Opportunity

    New Product Pipeline Provides Significant Growth Opportunity* (Post Merger) 2015 2016 2017 2018 2019 2020 U.S. CHEVAS Europe THORACIC CHEVAS Asia Pacific(Japan)(Japan)(Japan)(China) CHEVAS (Brazil, Argentina) Latin America CHEVAS (Argentina)(Brazil) * Post-merger estimated regulatory approvals

  16. Slide 16: Creating a Leader in Growth and Innovation

    Creating a Leader in Growth and Innovation Increased revenue growth Broad AAA product line Expanded global sales force Significant clinical evidence Robust new product pipeline Improved profitability

  17. Slide 17: Financials & Forecast

    Financials & Forecast Vaseem Mahboob Chief Financial Officer

  18. Slide 18: Transaction Overview

    Transaction Overview ? Aggregate value of $155 million (based on a $10.00 Endologix share price)(3) $6.19 implied stock value of TriVascular shares; value will fluctuate with Endologix share price through closing Transaction ? ~$19 million in cash Terms ~$9 million for intrinsic value of outstanding

  19. Slide 19: Synergy Model

    Synergy Model ELGX TRIV NewCo NewCo 2015 2015(3) 2015 Fcst 2020 Fcst Comments Sales $154-$157M $36-39M $190-$196M $425-$480M 20% CAGR(2) Gross Margin %(1) 68% 62% 67% 74% +7 pts Investing at industry R&D % ~25% ~50% ~30% ~12% Standards SG&A % ~70% ~150%+ ~85% ~40% Sales leverage Cash flow positive &

  20. Slide 20: Line Of Sight To Profitability

    Line Of Sight To Profitability (*) 2015 Operating Loss(*) 2020 Operating Profit $80 $100 $(40) $(50) ELGX TRIV Low end High end ? Volume leverage & sales force productivity ? Heavy Investments in Sales & Marketing ? R&D investment levels at par with top tier med ? Clinical & R&D initiatives … manage

  21. Slide 21: Key Financial Measures

    Key Financial Measures PROFORMA BALANCE SHEET METRICS SHARE COUNTS ($ millions)($ millions) Q3 15 Q4 15 Outstanding Q3 15 Q4 15 Cash & Cash Equivalents 118 210 TRIV 20.4 20.6 Endologix 67.8 68.3 Trade AR 34 36 Inventory 43 41 Weighted Average TRIV 20.3 20.5 All Other Assets 114 115 Endologix 67.6 68

  22. Slide 22: Financial Summary: Key Takeaways

    Financial Summary: Key Takeaways ? Fundamentals strong; line of sight to synergies ? Integration execution plans in place, target execution by 2Q/3Q ; experienced team ? Path to cash flow positive year earlier than strat plan ? Goal: Build a business growing 20% with operating leverage

  23. Slide 23: EVAS Global Registry

    Andrew Holden, MBChB Auckland City Hospital Auckland, NZ EVAS Global Registry

  24. Slide 24: EVAS FORWARD Global Registry: One Year Outcomes

    EVAS FORWARD Global Registry: One Year Outcomes VEITH SYMPOSIUM NOVEMBER 19, 2015

  25. Slide 25: Disclosures and Disclaimers

    Disclosures and Disclaimers ? Andrew Holden MBChB, FRANZCR, EBIR – Clinical Investigator for Endologix Inc. – Medical Advisory Board Member for Endologix Inc.

  26. Slide 26: Disclaimers

    Disclaimers ? CAUTION: Nellix® EndoVascular Aneurysm Sealing System is an investigational device. Limited by federal (or United States) law to investigational use only. ? Nellix is approved in Europe. For Nellix EndoVascular Aneurysm Sealing System, prior to use, refer to the “Instructions for Use”

  27. Slide 27: EVAS FORWARD Global Registry: Design and Status

    EVAS FORWARD Global Registry: Design and Status Total Patients ? Principal Investigators(n=300*) – Andrew Holden, MBChB, Auckland, NZ – Matt Thompson, MD, London, UK Cohort 1 ? 300 patients, 30 centers with five year follow-up(n=200) ? Real-world experience; no prospective screening Cohort 2 of pati

  28. Slide 28: Cohorts

    Cohorts Cohort 1 Cohort 2 Cohort 3 Cohort 4 66.9% 13.0% 12.7% 7.4% N=200 N=39 N=38 N=22 Neck Length ? 10mm Neck Length 5 -10mm Neck Length < 5mm rAAA; EVAR revision; Infrarenal Angle ? 60 Infrarenal Angle 61—90 Infrarenal Angle > 90 AUI; Isolated iliac Juxtarenal / Pararenal aneurysm

  29. Slide 29: Baseline Aneurysm and Vascular Characteristics

    Baseline Aneurysm and Vascular Characteristics Parameter Neck Length < 5mm Neck Length ? 10mm Neck Length 5 -10mm Infrarenal Angle > 90° Infrarenal Angle ? 60 Infrarenal Angle 61°—90° Juxtarenal—Pararenal Maximum Sac Diameter, mm 59 (55-65) 59 (56-64) 63 (56-70) Neck Length, mm 27 (19-39) 9 (7-18) 5

  30. Slide 30: AAA Complexity across All-Comer Registries

    AAA Complexity across All-Comer Registries EVAS Global Registry (n=300) 50% 46% ENGAGE Registry (n=1262) GREAT Registry (n=400) 40% 30% 20% 17% 13% 8% 10% 6% 5% 2% 1.5% n/r 0% 0.1% 0.5% 0.6% n/r 0% Neck Length Conical Neck Angle Chimney Iliac <10mm Neck >60° Procedure diameters >25mm

  31. Slide 31: Major Adverse Events

    Major Adverse Events ?30 days 31d – 1yr Classification n=277 n=272 All Cause Death 3 (1.1%) 11 (4.0%) Peri-operative mortality 3 (1.1%) - AAA-related mortality—1 (0.4%)* Renal Failure 0 2(0.7%) Myocardial Infarction 2(0.7%) 1(0.4%) Bowel Ischemia 0 0 Respiratory Failure 2(0.7%) 2(0.7%) Stroke 1(0.4%

  32. Slide 32: Freedom from All Endoleak

    Freedom from All Endoleak Through 1 yr 94.5%

  33. Slide 33: Type Ia Endoleak – Most Common Causes

    Type Ia Endoleak – Most Common Causes Stent Low stent Misalignment deployment

  34. Slide 34: Transcatheter Embolization Of Type IA Endoleak

    Transcatheter Embolization Of Type IA Endoleak

  35. Slide 35: Resolution of Type II Endoleak

    Resolution of Type II Endoleak 30d 6mo 1yr

  36. Slide 36: Freedom from Type II Endoleak

    Freedom from Type II Endoleak Through 1 yr 98.2% CONFIDENTIAL

  37. Slide 37: Persistent Endoleaks

    Persistent Endoleaks At 30 Days At 1 Year N=277 N=269 Endoleak (Total) 1.4% (4) 0.7% (2) Type IA 1.1% (3) 0.4% (1) Type IB — Type II 0.4% (1) 0.4% (1) Type III —

  38. Slide 38: Endoleaks at Year

    Endoleaks at 1 Year 12% 9.8% 10% 8% 6% 4% 2% 0.7% 0% EVAS ENGAGE Type 1A, 1B Type II Type III Type IV Undetermined ENGAGE Registry: Verhagen et al. LINC Symposium 2014

  39. Slide 39: Conclusions from Endoleak Data

    Conclusions from Endoleak Data The incidence of ? 30 day and 1 year endoleak remains very low The root causes are attributed to procedural factors – Low stent placement, stent misalignment, or no pre-fill Type 1A and 1B endoleak can be effectively treated Higher incidence of ? 30 day Core Laboratory

  40. Slide 40: Freedom from Secondary Intervention

    Freedom from Secondary Intervention 1Yr 98.2% Occlusion 1Yr 96.3% Endoleak 1Yr 92.3% All 277 267 264 262 258 256 205 144 74 277 265 260 257 254 252 202 142 75 31 277 261 256 252 249 247 199 140 74 31

  41. Slide 41: Patients with Secondary Interventions through Yr

    Patients with Secondary Interventions through 1 Yr 8% OFF IFU 40% 37% 7% 6% 4.5% 5% 5.6% 6.5% 4% 20% 18% 17% 3% 2% 3.2% 1% 1.6% 1.0% 0% 0% EVAS ENGAGE GREAT ?30d 31d- 1yr ENGAGE Registry : Verhagen H. LINC Symposium 2014 GREAT Registry: Verhoeven E. et al. EJVES 2014;48:131-37

  42. Slide 42: Freedom from Aneurysm-Related and All-Cause Mortality

    Freedom from Aneurysm-Related and All-Cause Mortality 1 Yr ARM 98.2% 1 Yr ACM 94.8%

  43. Slide 43: Mortality and MI through Year

    Mortality and MI through 1 Year EVAS ENGAGE GREAT ASA Class III/IV 64% 52% 63% Cardiac History 55% 53% 39% All Cause Death 5.1% 7.4% 7.0% AAA-related mortality 1.4% 1.5% NR Myocardial Infarction 1.1% 1.8% ENGAGE: Stokmans et al. EJVES 2012 / Broos et al. J Vasc Surg 2015 GREAT: Verhoeven et al. EJVE

  44. Slide 44: All-Cause and Aneurysm-Related Mortality

    All-Cause and Aneurysm-Related Mortality EVAS and ENGAGE ARM ACM ENGAGE: Stokmans et al. EJVES 2012;44:369-75

  45. Slide 45: Conclusions – Year Follow Up

    Conclusions – 1 Year Follow Up Impressive results in the first-ever prospective, EVAS all-comers clinical study showing durability of repair Low endoleak and reintervention rates in complex patient population Excellent one year aneurysm related and overall survival outcomes Longer follow-up and addi

  46. Slide 46: Treatment of Complex AAA

    Prof. Matthew Thompson St. George’s University London, UK Treatment of Complex AAA

  47. Slide 47: EVAS for Complex AAA

    EVAS for Complex AAA Matt Thompson St Georges Vascular Institute, London, UK MT 2015

  48. Slide 48: Disclaimers

    Disclaimers CAUTION: Nellix® EndoVascular Aneurysm Sealing System is an investigational device. Limited by federal (or United States) law to investigational use only. Nellix is approved in Europe. For Nellix EndoVascular Aneurysm Sealing System, prior to use, refer to the “Instructions for Use” for

  49. Slide 49: Complex AAA: Aneurysms Involving Visceral Segment

    Complex AAA: Aneurysms Involving Visceral Segment 14% Suprarenal Type IV TAAA ~36% of 7% No Neck AAA Market <5mm 15% Short Neck <10mm MT 2015

  50. Slide 50: Change in Endovascular Practice SGVI

    Change in Endovascular Practice SGVI Neck Length > 15mm Outside Proximal Neck IFU (d/ l) 100% 35% 30% 90% 25% 20% 80% 15% 10% 70% 5% 60% 0% MT 2015

  51. Slide 51: Endovascular Treatment of Juxta-Renal Aneurysms

    Endovascular Treatment of Juxta-Renal Aneurysms Large gains in absolute risk reduction High open elective mortality High turn down rate (41%) rAAA mortalty dramatically increased when neck shorter than 15mm MT 2015

  52. Slide 52: EVAR In Challenging Aortic Morphology

    EVAR In Challenging Aortic Morphology 70% reintervention rate 5y MT 2015 Karthikesalingam PLOS One 2015 10 (7)

  53. Slide 53: Custom Made Fenestrated Grafts

    Custom Made Fenestrated Grafts “Gold standard” at present Technically challenging – good success Significant “turn down” rate (50%) (manufacturing constraints, morphology) Delay to treatment Off shelf fenestrated treat lower proportion with higher technical difficulty Banno et al JVS 2014; 60: 31 MT

  54. Slide 54: Custom Made Fenestrated Grafts – Reintervention and Mortality

    Custom Made Fenestrated Grafts – Reintervention and Mortality Mortality Mortality Mortality 2% 7.8% 28% Early reintervention 7% MT 2015 Globalstar Circ 2012; 125: 2707 Patel et al JVS 2015; 62: 319

  55. Slide 55: EVAR and Parallel Grafts for Juxta-Renal AAA

    EVAR and Parallel Grafts for Juxta-Renal AAA Near universal applicability Early results better than expected – durability Issue is seal – gutters / endoleaks Pericles Registry – Type 1 2.9% Improved seal with polymer based technology MT 2015 Donas et al Ann Surg 2015; 262: 546

  56. Slide 56: EVAS and Parallel Grafts

    EVAS and Parallel Grafts MT 2015 Off label use

  57. Slide 57: Parallel Grafts and EVAS – Current Practice SGVI

    Parallel Grafts and EVAS – Current Practice SGVI fEVR / open turndown Plan to increase sealing zone to 2cm – parallel sided aorta Now approaching standard of care Technique evolved Adjunctive stents for parallel grafts crucial MT

  58. Slide 58: Neck 6-25mm

    Neck 6-25mm MT 2015 ©: George's ‘VASCULAR INSTITUTE

  59. Slide 59: MT 2015 St George’s

    MT 2015 St George’s VASCULAR INSTITUTE

  60. Slide 60: Visceral Stenting/Placement of Protection Balloons/ EVAS

    Visceral Stenting/Placement of Protection Balloons/ EVAS MT 2015

  61. Slide 61: MT 2015 St George’s

    MT 2015 St George’s

  62. Slide 62: Parallel Grafts and EVAS – SGVI Series (April 2015)

    Parallel Grafts and EVAS – SGVI Series (April 2015) 47 patients: 8 (3)/7 (2)/ 32 (1) 3 ruptured AAA / 4 mycotic / 7 EVAR revisions 2 deaths (1 rupture / 1 elective) 3 endoleaks (all resolved with embolisation) 1 limb occlusion / 1 renal stent stenosis MT 2015 DRAFT RESULTS

  63. Slide 63: Validation Work for Parallel Grafts / EVAS

    Validation Work for Parallel Grafts / EVAS MT

  64. Slide 64: Validation Work for Parallel Grafts / EVAS

    Validation Work for Parallel Grafts / EVAS MT

  65. Slide 65: Post-market registry of the Nellix System with parallel grafts

    Post-market registry of the Nellix System with parallel grafts in juxta- renal, opera-renal and supra-renal AAA Retrospective and prospective Open-label, single-arm, no prospective screening 200 patients, up to 10 international centers with 5y F/U Endpoints typical of EVAR therapy in complex AAA MT

  66. Slide 66: Expanded Indications for EVAS

    Expanded Indications for EVAS Promising use of new technology – therapeutic gap Theoretical advantages in using polymer based sealing Early results acceptable – approaching first line therapy Proof of concept – testing Long term results and endograft durability MT 2015

  67. Slide 67: TriVascular Ovation

    David J. Minion, MD University of Kentucky College of Medicine, Lexington, KY TriVascula Ovation

  68. Slide 68: Ovation Abdominal Stent Graft Platform

    Ovation® Abdominal Stent Graft Platform A Paradigm Shift for EVAR

  69. Slide 69: Polymer Technology

    Polymer Technology OTHER STENT GRAFT Stent and fabric compressed in ame space within -atheter allows for significant reduction in ‘Any reduction in profile must come trom compromising

  70. Slide 70: Polymer Technology

    Polymer Technology “Injectable Architecture” reduces profile while increasing conformability. Sets to the consistency of a pencil eraser Long-term cushion effect on proximal aortic neck

  71. Slide 71: Why is that important?

    Why is that important?

  72. Slide 72: Advantages of Polymer Technology

    Advantages of Polymer Technology Reduced Profile

  73. Slide 73: Lowest FDA-Approved Profile

    Lowest FDA-Approved Profile

  74. Slide 74: The Perils of Access

    The Perils of Access

  75. Slide 75: Iliac Rupture

    Iliac Rupture

  76. Slide 76: Iliac Avulsion

    E lliac Avulsion

  77. Slide 77: Persistent EVAR Challenges

    Persistent EVAR Challenges Characteristics of Hostile Narrow Access Vessels Access Anatomy • Narrow (<6mm) • Occluded 5.3 3.2 Tortuous mm mm Calcified • Aneurysmal Access Vessel Tortuosity 40% Patients < 6mm* M2S Database – 43,000 CT Scans 55% Female Patients <6mm** (CHAP) Collaborative effort – 1,0

  78. Slide 78: Abdominal Aortic Aneurysm Repair

    Abdominal Aortic Aneurysm Repair Drive to Safely Expand EVAR While Reducing Invasiveness Open Surgical Repair EVAR Surgical Cutdown Percutaneous EVAR Open EVAR Source Day Mortality 4.3% 1.8% New England Journal of Medicine 2010; 362:1863-1871 Journal of Vascular Surgery, March 2010, Turnbull et al;

  79. Slide 79: Advantages of Polymer Technology

    Advantages of Polymer Technology Reduced Profile Custom Molded Sealing

  80. Slide 80: Unique Sealing Mechanism

    Unique Sealing Mechanism

  81. Slide 81: Why is that important?

    Why is that important?

  82. Slide 82: Irregular, Calcified Plaque

    Irregular, Calcified Plaque

  83. Slide 83: Standard Stent Graft

    Standard Stent Graft

  84. Slide 84: Polymer Sealing Technology

    Polymer Sealing Technology

  85. Slide 85: Persistent EVAR Challenges

    Persistent EVAR Challenges Characteristics of Hostile Reverse Tapered Necks At Inferior Neck Anatomy Renal Artery Short Aortic Necks At IR + 5 (<15mm) • Reverse Tapered Necks At IR + 13 Calcium • Thrombus • Severe Angulation Calcium/Thrombus lined Necks Large Diameter 48% Patients < 15mm Necks* M2S

  86. Slide 86: Custom Molded Seal

    Custom Molded Seal Self Expanding Stent Graft Wire and fabric grafts create discontinuous points of apposition in irregular and/or tapered anatomy Note: FEA simulations illustrate the spectrum of wall apposition from low (blue) to high (red) Ovation Prime Stent Graft Ovation Prime sealing ring creat

  87. Slide 87: Literally “Water-Tight”

    Literally “Water-Tight” Colored Water Sealing Ring Ovation Prime graft sealing colored water in clear tube*

  88. Slide 88: Advantages of Polymer Technology

    Advantages of Polymer Technology Reduced Profile Custom Molded Sealing Depressurizes the “Neck” (Sealing Zone)

  89. Slide 89: Ovation System Protects the Aortic Neck

    Ovation System Protects the Aortic Neck Self expanding stent graft systems exert continual radial force which can lead to neck dilation, device migration, endoleaks and aneurysm rupture Untreated Aneurysm Self Expanding Stent Graft Ovation Stent Graft Blood Pressure Stent Outward Radial Force

  90. Slide 90: Why is that important?

    Why is that important?

  91. Slide 91: Late Failure: Standard Stent-Graft

    Late Failure: Standard Stent-Graft Years 6 Years

  92. Slide 92: Late Failure: Standard Stent-Graft

    Late Failure: Standard Stent-Graft Years 9 Years

  93. Slide 93: Ovation Platform Protects the Aortic Neck

    Ovation Platform Protects the Aortic Neck Ovation Global Pivotal study demonstrates encouraging results with stable neck diameter and durable seal through 4 years due to the unique sealing ring technology which creates no chronic outward force and insulates the neck from blood pressure. Aortic Neck

  94. Slide 94: Case Studies Demonstrate Stable Aortic Neck Diameters

    Case Studies From Ovation Global Pivotal Trial Demonstrate Stable Aortic Neck Diameters Straightforward No aortic neck growth at 4 years Pre-case Post-30 day Post 4-year Reverse Tapered Neck No aortic neck growth at 2 years Pre-case Post-30 day Post 2-year Heavy Calcification No aortic neck growth a

  95. Slide 95: Clinical Evidence for the Ovation System

    Clinical Evidence for the Ovation System

  96. Slide 96: Ovation Global Pivotal Trial

    Ovation Global Pivotal Trial Baseline Aortoiliac Mean ± SD Min, Max Characteristics Aortic diameter 13mm below renal artery (mm)1 22.7 ± 3.1 16.6, 32.3 Juxtarenal angle (degrees)1 19.1 ± 13.5 0.0, 60.0 Proximal neck length (mm)2 22.9 ± 12.5 1.0, 50.0 Aortic aneurysm diameter (mm)2 53.6 ± 9.0 37.8, 9

  97. Slide 97: Ovation Global Pivotal Trial results

    Ovation Global Pivotal Trial 4 year results of the global pivotal clinical study to evaluate the safety and effectiveness of the TriVascular Ovation Abdominal Stent Graft System. Technical Success1 All N=161 Defined as successful, delivery and deployment of one aortic body and two iliac limbs 100% 0

  98. Slide 98: Clinical Evidence to Validate the Ovation Platform

    Clinical Evidence to Validate the Ovation Platform Over 8,000 patients worldwide have been treated Ovation Abdominal Stent Graft platform, with over subjects in a tightly controlled study or registry Patient demographics, anatomical characteristics, procedural characteristics indicate a challenging

  99. Slide 99: Why not use it for everything?

    Why not use it for everything?

  100. Slide 100: Eurostar Classification of AAA

    Eurostar Classification of AAA

  101. Slide 101: Slide 101

  102. Slide 102: Slide 102

  103. Slide 103: Thank You

    Thank You NASDAQ: TRIV www.trivascular.com

  104. Slide 104: Summary

    Summary John McDermott Chief Executive Officer

  105. Slide 105: Summary

    Summary Most Comprehensive AAA Product Line Robust New Product Pipeline Traditional AAAs, Complex AAAs and Thoracic ~30% Larger Global Sales Force Significant Clinical Evidence Top Tier Forecasted Financial Performance: Revenue CAGR of 20% Gross margins 70%+ EBITDA margin of 20% by 2020

TriVascular Technologies — Merger or Acquisition (November 2015) on 6ix